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Abstract
Improvements in ischemic heart disease (IHD) management have been unbalanced between sexes, with coronary microvascular
dysfunction considered the likely underlying reason. The Endocrine Vascular disease Approach (EVA) is an observational study
(Clinicaltrial.gov NCT02737982) aiming to assess sex and gender interactions between coronary circulation, sexual hormones,
and platelet function. Consecutive patients with IHD undergoing coronary angiography will be recruited: (1) to assess sex and
gender differences in angiographic reperfusion indexes; (2) to evaluate the effects of estrogen/androgen on sex-related differences
in myocardial ischemia; (3) to investigate the platelet biology differences between men and women with IHD; (4) to verify sex-
and gender-driven interplay between response to percutaneous coronary intervention, platelets, sex hormones, and myocardial
damage at baseline and its impact on 12-month outcomes. The integration of sex and gender in this translational project on IHD
will contribute to the identification of new targets for further innovative clinical interventions.
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Abbreviations
1VD One-vessel disease
2VD Two-vessel disease
3VD Three-vessel disease
ACS Acute coronary syndrome
AR Androgen receptors
CAD Coronary artery disease
CMD Coronary microvascular dysfunction
CMR Cardiac magnetic resonance
CVD Cardiovascular disease
E2 Estradiol
eCRFs Electronic case report forms
ER Estrogen receptor
GP Glycoprotein
IHD Ischemic heart disease
INOCA Ischemia and no obstructive CAD
MACE Major adverse cardiovascular events
MBG Myocardial blush grade
MMAS-4 Morisky Medication Adherence Scale—4 Items
NOS Nitric oxide synthase
NOX2 NADPH oxidase 2
NSTEMI Non-ST elevation
myocardial infarction
PCI Percutaneous coronary intervention
STEMI ST elevation myocardial infarction
(c)TFC (corrected) TIMI frame count
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Rationale
Integration of Sex- and Gender-Based Approaches
in Cardiovascular Research: The Case of Ischemic
Heart Disease
Even though the individual’s sex is among the most important
modulators of cardiovascular disease (CVD) risk and response
to treatment, the integration of sex in research and clinical
decision-making is yet overlooked [1–3]. In the era of preci-
sion medicine, reporting on sex- and gender-related variables
in clinical trials has become necessary in order to understand
how they interact and influence cardiovascular health [1–3].
However, some issues stem from the terminology biases
among published literature: while the term Bsex^ should be
used when reporting biological aspects, the term Bgender^ is
more appropriate when reporting gender identity and
psychosocial/cultural factors [1].
Ischemic heart disease (IHD) is the main cause of death
among women and men [4]. Nonetheless, IHD has been per-
ceived as a primarily Bmale disease^, and Bevidence-based^
clinical standards have been based on male pathophysiology
and outcomes in basic and clinical research [5]. The low par-
ticipation of women in clinical trials for CVD is cause of
concern, especially in IHD patients [6, 7]. In fact, despite the
decrease in CVD mortality over the past decade, trends are
less favorable in women [8]. Several studies report clear sex
discrepancies in clinical outcomes for IHD patients treated
either with conservative or invasive approach (i.e., percutane-
ous coronary intervention (PCI)) [5, 7]. For example, in acute
coronary syndrome (ACS), the benefits of early invasive strat-
egy resulted less effective in women with high-risk profiles [9,
10], exhibiting a higher unadjusted in-hospital mortality in
women undergoing PCI [9, 10]. So far, only two studies, the
BVariation in Recovery: Role of Gender on Outcomes of
Young AMI Patients^ [11] and BGENdEr and Sex
determInantS of cardiovascular disease: From bench to
beyond-Premature Acute Coronary Syndrome^ [12, 13], have
explored the multilevel interactions between sex and gender in
influencing CVD development and management in young pa-
tients with ACS [14].
Beyond Epicardial Obstructive Coronary Artery
Disease, Microvascular Dysfunction, and its
Assessment
Microvascular perfusion impairment, not explained by an epi-
cardial critical stenosis, is a common finding in IHD and it
appears to provide an adjunctive prognostic value in IHD
patients [15, 16]. Therefore, the term coronary microvascular
dysfunction (CMD) was coined to provide an overarching
definition that encompasses different clinical scenarios. The
conundrum of CMD ranges from a reduced coronary flow
reserve not explained by a flow-limiting epicardial stenosis
to the coronarymicrovascular impairment coexistingwith cor-
onary artery disease (CAD). Specifically, CMD can be detect-
ed in IHD patients with obstructive CAD undergoing urgent
(reperfusion CMD) or elective PCI (interventional CMD), as
well as in cases of ischemia and no obstructive CAD
(INOCA) [17]. CMD can only be indirectly assessed using
invasive and noninvasive techniques that measure parameters
strongly dependent on the functional and structural integrity of
coronary microcirculation [18]. In the coronary catheteriza-
tion laboratory, CMD is commonly diagnosed by evaluating
coronary blood flow before and after administration of aden-
osine with a Doppler-tipped guide wire in the coronary artery
[19]. However, the corrected thrombolysis in myocardial in-
farction (TIMI) frame count (cTFC) and myocardial blush
grade (MBG) provide easy and accessible angiographic in-
dexes of coronary blood flow that do not require additional
coronary artery instrumentation [20]. The intra- and inter-
observer reproducibility of cTFC and MBG is acceptable,
and dye injection rate and catheter size do not affect its mea-
surement [21, 22]. It is noteworthy that cTFC and MBG have
been shown to correlate with other invasive and non-invasive
measures of coronary blood flow [23–26]. The cTFC, used as
a surrogate marker of coronary blood velocity, predicts coro-
nary microvascular status [27]. Interestingly, abnormal cTFC
andMBG have also been related to worse prognosis, although
mostly in patients with ACS [28–30]. No association between
cTFC and major adverse cardiovascular events (MACE) ex-
cept angina hospitalization was reported in a pilot study of
Women’s Ischemia Syndrome evaluation considering 298 pa-
tients with INOCA (defined as no stenosis ≥ 50% in any epi-
cardial vessel), but the study population included only women
[31]. Therefore, it remains unclear whether the prognostic
implications of an abnormal cTFC or MBG vary in different
categories of male and female patients with IHD-for example,
in patients varying in clinical presentation, coronary anatomy,
or type/extension of coronary lesions.
Preliminary data suggest that cardiac magnetic resonance
(CMR) can identify a specific CMD pattern in IHD women
[32], suggesting its potential role for recognizing sex-related
differences in the conundrum of IHD [33]. This is raising
interest in the potential use of CMR, especially to target wom-
en with atypical chest pain and to detect the extent of proce-
dural CMD [18, 34, 35]. Over 100 women with CMD, diag-
nosed by invasive coronary reactivity testing, have showed
reduced myocardial perfusion reserve index with vasodilator
stress first-pass perfusion CMR compared with an age-
matched reference group (N = 21). Moreover, the presence
of diffuse myocardial fibrosis, documented by native myocar-
dial T1 values assessed by CMR, has been reported in 14
women with CMD without obstructive CAD [32]. However,
these data were collected in a female-only population and they
lack the comparison with a matched male group.
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Mechanisms Responsible for Microvascular
Dysfunction in Ischemic Heart Disease Patients: A
Landscape to Explore Under the Lens of Sex
Microvascular impairment seen in diagnostic angiography
and after PCI may be responsible for different degrees of
myocardial injury and may represent an in vivo human model
of ischemia–reperfusion myocardial damage [36]. The impair-
ment of coronary flow owing to functional (i.e., impaired di-
lation or increased constriction of coronary microvessels) and/
or structural abnormalities of the microcirculation can be
sustained by several mechanisms [37, 38]. Recently, it has
been proposed that CMD in women plays a central role in
the genesis of symptoms and myocardial ischemia, specifical-
ly in the case of INOCA.Womenmore frequently experienced
persistent ischemic symptoms, regardless of revascularization
procedures, as compared to men. Therefore, CMD should be
investigated in order to elucidate sex differences in clinical
outcomes of IHD patients [39, 40].
Notably, a sex-specific response to myocardial ische-
mia has been demonstrated in pre-clinical studies [41].
It is unclear which factors contribute to sexual dimor-
phism in IHD; nevertheless, sex hormones with their
multiple cardiovascular effects could play a crucial role
[42], especially considering that the estrogen/androgen
balance is involved in the cardioprotective response to
ischemia–reperfusion injury [43].
In experimental models, females are at lower risk of
ischemia–reperfusion damage and estradiol (E2) administered
acutely to males can reduce the infarct size [44–46]. Indeed,
the estrogen receptor (ER) beta versus ER-alpha receptor-me-
diated responses and the relative importance of genomic ver-
sus non-genomic effects are the subjects of considerable de-
bate [43, 47]. The cardioprotective role of E2 in the modula-
tion of ischemia–reperfusion injury has been extensively in-
vestigated: inmodels, E2 acts at multiple cellular levels during
ischemia–reperfusion, including cardiomyocytes and fibro-
blasts [46, 48–51].
Despite plausible pathological pathways linking endog-
enous sex hormones and cardiovascular disease, prospec-
tive clinical studies have been contradictory. The imbal-
ance between testosterone and E2 was looked at as a po-
tential mechanism of ischemia and CAD development
[52–55]. Recently, in postmenopausal women participat-
ing in the MESA (Multi-Ethnic Study of Atherosclerosis),
a higher testosterone/E2 ratio was shown to be associated
with the development of IHD and heart failure events,
whereas higher levels of E2 are associated with a reduced
risk of ischemic events [56]. Moreover, low levels of se-
rum anti-inflammatory biomarkers are positively associat-
ed with sex hormones in male CAD patients [57] suggest-
ing that the imbalance between sex hormones can influ-
ence the development of CAD.
Platelets: Evidence Suggesting Sex Differences Sheds
Light on the Potential Role of Hormone Balance
Sex hormones operate at the cellular level, including vas-
cular cells and activated cells recruited at the site of the
athero-thombotic process, primarily platelets [58]. Sex
differences in platelet reactivity have been reported in
response to agonists, regardless of any ongoing anti-
platelet therapy [59].
Ex vivo evidence showed that platelets from women
without CAD are more reactive than those of men in re-
sponse to standard concentrations of agonist [60–62], with
a greater expression (50–80% higher compared to men) of
glycoprotein (GP) IIb/IIIa receptors. Among patients,
platelets from women, and in particular Caucasian wom-
en, bound more fibrinogen in response to low and high
concentrations of ADP and showed more spontaneous ag-
gregation compared to men after adjustment for multiple
cardiovascular risk factors [63].
Mechanisms responsible for differences in platelet
function are largely unknown. Estrogen and androgen re-
ceptors are expressed in platelets [58]; therefore, platelets
are an excellent model for studying the non-genomic ef-
fects of hormones [64]. Specifically, human platelets have
been shown to express only ER-beta and androgen recep-
tors (AR). The effects of E2 and of other forms of estro-
gen, as well as those of testosterone, have been only par-
tially explored and with conflicting results. Ex vivo acute
treatment of platelets with estrone or estriol was shown to
increase aggregation in response to common agonists
[65]. Conversely, 3-month replacement therapy with es-
trogen induced a decrease in agonist-induced platelet ag-
gregation in treated patients compared to control groups
[66]. Accordingly, chronic treatment with high levels of
E2 in experimental models (i.e., mice) produced a signif-
icant reduction in platelet responsiveness both ex vivo and
in vivo, with a simultaneous increase of bleeding time and
resistance to thromboembolism [67].
Concerning the role of AR in the biology of platelet func-
tion, rat models have showed that the ex vivo aggregation of
platelets isolated from males was greater than that exhibited
by those isolated from females and correlates with higher
levels of androgens [60]. Consistently, platelet aggregation is
reduced following castration in male rats and restored by tes-
tosterone administration [68]. The acute treatment of both rat
and human platelet-rich plasma with testosterone amplified
the aggregation induced by common agonists, indicating its
rapid non-genomic responses [69].
Platelets also play a key role in athero-thrombotic mecha-
nisms. Therefore, exploring the effect of sex hormones on
platelet function in IHD is a step forward toward a better
characterization of biological differences in IHD between
men and women.
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EVA Research Hypothesis and Aims
The research hypothesis is that women with IHD have a
higher proportion of CMD due to a higher release of
platelet-derived vasoconstrictor molecules such as thrombox-
anes, despite anti-platelet therapy. This status of hyper-
activation might be modulated differentially by sex hormone
balance among sexes according to age (Fig. 1). Further evi-
dence on platelet biology and sex hormone interplay will pro-
vide mechanistic insights to understand CMD. Platelet activa-
tion markers will potentially be used as breakthrough innova-
tive biomarkers to better predict outcomes of IHD patients.
We plan to conduct an observational study on patients af-
fected by IHD undergoing angiography and/or PCI. Main ob-
jectives of EVA are:
1. To assess the sex–gender differences in severity of micro-
vascular reperfusion damage in patients with IHD;
2. To evaluate estrogen/androgen effects on sex-related dif-
ferences in myocardial ischemia–reperfusion damage oc-
curring during PCI;
3. To investigate the differences in terms of platelet function
between men and women affected by IHD and matched
by age and clinical characteristics, according to CMD and
CAD type;
4. To verify sex- and gender-driven interplay between the
response to PCI procedure, platelet function, sex hor-
mones, reperfusion imaging, and myocardial damage se-
verity at baseline and its impact on outcomes at 12-month
follow-up.
Methods
Study Design and Population
The BEndocrine Vascular disease Approach^ (EVA) project
(ClinicalTrials.gov identifier NCT02737982) was planned as
an observational cohort prospective study. The flow chart of
the study and the description of variables that will be
considered are summarized in Table 1.
A registry will be built up of men and women aged 18 and
older with suspected IHD who were referred to the catheteri-
zation laboratory in order to undergo coronary angiography
and/or PCI. Patients will be recruited according to the eligibil-
ity criteria reported in Table 2. Therefore, the EVA study pop-
ulation will include patients with stable CAD, patients with
non-STelevation (NSTE) ACS, and patients with STelevation
myocardial infarction (STEMI).
The study will be conducted in full conformance with the
principles of the Declaration of Helsinki, the laws and regula-
tions of Italy, or whichever affords the greater protection to the
individual. The study has obtained the required authorization
by the local Ethics Committee of Policlinico Umberto I,
Sapienza University of Rome (reference 3786, 24/09/2015).
Written informed consent will be obtained from all patients.
Among the study population, we will select (1) pa-
tients undergoing urgent PCI, specifically subjects who
presented within 12 h of the onset of chest pain, who
had ST segment elevation of more than 0.1 mV in two
contiguous leads, and for whom the clinical decision
was made to treat with PCI (STEMI); (2) patients with
Fig. 1 The EVA hypothesis: platelets, coronary microvascular dysfunction, and unbalanced clinical outcomes in women and men with ischemic heart
disease
J. of Cardiovasc. Trans. Res.
NSTE ACS defined by acute chest pain but no persis-
tent ST segment elevation. ECG changes may include
transient ST segment elevation, persistent or transient
ST segment depression, T-wave inversion, flat T waves,
or pseudo-normalization of T waves or the ECG may be
normal. Myocardial ischemia can occur with (myocardi-
al infarction–NSTEMI) or without cell loss (unstable
angina); (3) patients undergoing coronary angiography
and elective PCI for stable angina, with stress test
inducible myocardial ischemia and de novo native cor-
onary lesion with a stenosis of less 50% (no obstructive
CAD) or > 50% stenosis in any epicardial artery (mono-
vessel obstructive CAD). Patients will be treated accord-
ing to standard guidelines based on the CAD type, ei-
ther with PCI or coronary artery bypass graft.
The recruitment phase started in April 2016 and, cur-
rently, 200 patients have already been included in the
study.
Table 1 EVA Study design
STUDY TIMEFRAME
Post-enrolment Close-out
TIMEPOINT 3 months
6 
months
9 
months
12 
months
Study 
completion
ENROLMENT:
Eligibility screen X
Informed 
consent X
Coronary 
Angiographic 
Assessment
X
Laboratory Test X X
Clinical, 
pharmacological, 
gender-related 
data collection
X X
ASSESSMENTS:
Phone call 
interview X
Ambulatory Visit X
Outcomes 
Recording
Data-analysis X
In hospital
Enrolment
Baseline
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Clinical, Pharmacological, and Gender-Related Factors
We will record complete information regarding (1) anthropo-
metric data including height, weight, blood pressure, and heart
rate; (2) socioeconomic status and gender-related factors: mar-
ital status, education level, income, physical activity (self-ad-
ministered questionnaire), independent functional status Duke
Activity Status Index [70], alcohol intake, smoking habits,
perceived stress at work and at home, personality traits, and
psychosocial characteristics and support [12, 71]; (3) cardio-
vascular risk factors (including familiar history of cardiovas-
cular disease; hypertension; dyslipidemia, diabetes, previous
cardiovascular events including previous MI and prior stent
implantation); (4) symptom evaluation through standardized
questionnaires [72, 73]; (5) dietary habits [74]; and (6) phar-
macological therapy and Morisky Medication Adherence
Scale—4 Items [75].
Coronary Angiography Assessment
Coronary angiography will be performed according to stan-
dard methods. Qualitative and quantitative coronary angio-
graphic analyses will be conducted by a core laboratory
blinded to patient data. Time of procedure and timing to access
at the catheterization after the first medical contact will be
collected to explore chronobiology aspects.
Corrected TIMI Frame Count and Myocardial Blush Grade The
analysis of coronary flow will be done according to the TIMI
frame count method by Gibson et al. [20, 28]. Values above
the normal frame count will be considered suggestive of mi-
crocirculatory impairment. Themean TFC for each participant
will be calculated using the cTFC of left anterior descending,
left circumflex, and right coronary arteries. All participants
with a TFC greater than two standard deviations from the
normal published range in at least one of the three epicardial
coronary arteries will be accepted as having micro-coronary
slow flow, while those whose TFC falls within two standard
deviations of the published normal range will be considered as
having normal coronary flow.
The MBG [29] will be used to assess the filling and clear-
ance of contrast in the myocardium. A rest or post-PCI MBG
of less than 2 will define an impairment of coronary microcir-
culation [76].
Angiographic Definition of Extension and Localization of CAD
Based on angiography, we will classify IHD patients as fol-
lows: (1) ischemia with obstructive CAD, that is, ≥ 50% di-
ameter stenosis; and (2) ischemia with no obstructive CAD
(INOCA) < 50% diameter stenosis [17]. Based on the location
of the CAD obstruction, we will identify one-vessel disease
(1VD), two-vessel disease (2VD), and three-vessel disease or
left main coronary artery disease (3VD) groups.
Laboratory Measurements
Routine blood tests (e.g., cardiac troponin, as myocardial in-
jury index, whole blood count, creatinine level, glycemia, lip-
id profile, hepatic enzymes) performed during hospitalization
will be recorded.
The collection of biological samples for studies of platelet
function will be performed in accordance with the guidelines
suggested by the international literature and at scheduled time
points. Blood samples will be properly maintained until batch
analysis in freezers at − 80 °C. All samples will be coded to
ensure anonymity and entered in conjunction with clinical
data in a computerized database protected by double access
code/password. All assays will be performed in a blinded
fashion. The samples analyzed by immunoassay methods will
be tested in duplicate, and those with concentrations exceed-
ing the standard curve will be assayed again after appropriate
dilution. The results obtained will be compared with reference
values obtained in our laboratory on a reference population
(healthy subjects, both sexes, and aged from 25 to 80 years).
During the angiography, blood samples will be collected at
coronary and peripheral levels before and after PCI.
According to a previously reported study, the arterial sample
will be suitable for testing biomarkers of platelet function [77].
Moreover, a peripheral sample collection after 24 h will be
performed.
Given the close interaction between thrombosis and hor-
mone pathways, we plan to evaluate experimental biochemi-
cal markers of platelet function in association with sex hor-
mone profiles.
In every patient, regardless of sex, we will perform the
measurement of 17-beta estradiol (E2), luteinizing hormone
(LH), follicle-stimulating hormone (FSH), and free testoster-
one (BioT). The BioT/E2 ratio will be calculated. For women,
we will consider for the interpretation of results data
concerning the menopausal status and, if in pre-menopause,
Table 2 EVA study population eligibility criteria
Inclusion criteria Exclusion criteria
▪ Patients with ischemic heart
disease (acute or chronic)
undergoing percutaneous
coronary intervention
(urgent or elective)
▪ Written informed consent
▪ Both sexes
▪ Aged more than 18 years
▪ Life expectancy less than
12 months
▪ Active cancer (i.e., chemotherapy
or ≤ 5 years
from diagnosis)
▪ Pregnancy
▪ Previous coronary artery
bypass graft
▪ Documented moderate–severe
valvular heart disease
▪ Biological or mechanical valves
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the timing of the menstrual cycle in which the blood collection
was performed.
To better understand sex differences, plasma, serum, and cell
lysates opportunely prepared from the enrolled populations will
be collected and managed in an appropriate manner.
Furthermore, the platelet-rich plasma will be prepared for the
study of platelet aggregation, and in vivo markers of platelet
activation (i.e., thromboxane, soluble CD40 ligand, soluble P
selectin, isoprostanes) will be detected. Apoptotic processes, pro-
tein expression of estrogens and androgens, and their signaling
will all be measured in the cell lysates. Platelets will be used to
study signal transduction pathways of sexual hormone receptors,
nitric oxide synthase (NOS) phosphorylation, and oxidative
stress pathways including NADPH oxidase 2 (NOX2). In these
cell types, the protein expression of endocellular and membrane
receptors will also be studied using Western blot. The involve-
ment of the receptors will be investigated using specific inhibi-
tors, hormones, and specific agonists.
Using flow cytometry, we will analyze platelet-derived mi-
croparticles and surface receptors (i.e., CD40 ligand, P-
selectin, GPIIb/IIIa, CX3CR1, GPVI) from resting and acti-
vated platelets in vitro of patients with ACS versus age- and
sex-matched healthy individuals. Therefore, we could evalu-
ate the correlation between circulating molecules and
membrane-associated markers.
CMR Sub-Study
With the aim of better describing the CMR pattern of CMD in
IHD patients, we planned a pilot study including (1) patients
(N = 10; ratio W/M= 1:1) with mono-vessel obstructive CAD
undergoing PCI and (2) patients (N = 10; ratio W/M=1:1) un-
dergoing angiography that documented no obstructive coronary
diseasewith an impairment ofmicrovascular dysfunction defined
during angiography by aMBG < 2. Exclusion criteria will be (1)
standard contraindication to magnetic resonance; (2) severe ar-
rhythmia or tachycardia; (3) history or evidence of systemic au-
toimmune disorders, sarcoidosis, amyloidosis, or congenital
heart disease; and (4) chronic kidney disease stages 4 and 5
(glomerular filtration rate < 30 mL/min/1.73 m2).
The procedure will be performed within 7 days from angi-
ography to detect coronary microvascular dysfunction related
to the procedure according to standard protocol (i.e., first-pass
perfusion and the delayed post-contrast sequences). All CMR
studies will be analyzed off-line in consensus by two experi-
enced observers blinded to clinical information, using a work-
station with dedicated cardiac software.
Follow-Up Phase
The follow up-phase will include the in-hospital length of stay
and 1 year after discharge. A phone call interview within
3 months and an ambulatory visit at 12 months will be
performed.
Clinical, pharmacological, and behavioral information will
be re-assessed at the time of follow-up. Information
concerning the duration of in-hospital stay as well as any
adverse events before discharge will be collected. The letter
of discharge for each participant will be collected.
Reassessment of medication adherence, as well as psychoso-
cial and behavioral aspects will be checked at the scheduled
follow-up as well as the occurrence of new comorbidities.
Adverse clinical outcomes will be determined through the
medical chart reviews following the index angiography. Peri-
procedural and after-discharge complications with focus on
thrombotic and bleeding events will be recorded. Minor and
major bleeding events according to International Society on
Thrombosis and Hemostasis [78] and Bleeding Academic
Research Consortium [79], as well as recurrence of angina
symptoms will also be recorded during the follow-up phase.
All participants will be followed for 1 year to verify clinical
endpoints: early (30 days) and late mortality (12 months) for
cardiac-related events or for any other cause; recurrence of
acute coronary syndrome; need for re-interventions or coro-
nary artery bypass graft, complications related to PCI or re-
admission for cardiac-related cause (i.e., heart failure), or for
any other causes.
Data Collection, Management, and Quality Assurance
The EVA coordination group (V.R., M.P., S.B., A.L.) will
have full access to data and they will be responsible for the
data management, including quality check. Investigators will
be responsible for data entry into the electronic case report
forms (eCRFs). In case of discrepant data, the coordination
group will request data clarification, and if this should not be
sufficient, the patient will be excluded from the analysis. EVA
collaborators will receive training and a have access to a
checklist for appropriate eCRF completion. By using a vali-
dation plan integrated in the data entry software, data will be
checked for missing or contradictory entries and values out of
the normal range. A final database will be created and validat-
ed by the study coordinator. Patients’ identification names will
be registered by recruiting personnel. A series of consecutive
numbers will identify patients. Regular monthly meetings will
be conducted to check the sustainability of the project.
Source documents (paper or electronic) in which patient
data are recorded will be collected. They will include, but
not be limited to, hospital records, clinical and office charts,
laboratory notes, patient-reported outcomes, evaluation
checklists, pharmacy dispensing records, copies of transcrip-
tions that are certified after verification as being accurate and
complete, patient files with radiological images, and records
kept at medico-technical departments involved in the trial.
Source documents, required to verify the validity and
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completeness of data, must be retained per the policy for re-
tention of records.
Knowledge Translation
We will facilitate the dissemination of our research findings
through publications (open access) and presentations at na-
tional and international congress meetings making scientific
audiences aware of the findings and creating an interdisciplin-
ary network that may influence both individual and public
practice.
Statistical Analysis Plan
The data will be analyzed by appropriate statistics. Student’s t
test and Pearson correlation will be used for normally distrib-
uted variables. When necessary, log transformation will be
used to normalize the data, or appropriate non-parametric tests
will be employed (Mann–Whitney U test and Spearman rank
correlation test). Adjusted multivariate analyses will be used
to assess the differences and relationships between angio-
graphic, laboratory, and clinical characteristics, stratifying
the analysis on sex- and gender-related variables. Among the
pre-specified subgroup analyses, we will explore the clinical
presentation of ischemia (stable vs. acute coronary syndrome),
the type of disease (obstructive vs. non-obstructive disease),
traditional cardiovascular risk factors, medication adherence,
and the gender construct including gender identity, gender
role, gender relations, and institutionalized gender. We will
consider the interaction term between sex and hormones in
the changes of platelet biomarkers and angiographic index
of coronary flow.
All calculations will be made using appropriate statistical
software packages.
Sample Size Calculation Preliminary data reported a higher
rate of pathologic post-procedural MBG in women (50%)
compared to men (30%) despite a TIMI flow grade 3 after
PCI [80].
Therefore, the study requires 186 patients (93 per group,
ratio men/women 1:1) to detect a difference of 20% in MBG
< 2 at baseline and after PCI between men and women, with
an alpha error equal to 5% and a power of 80%. Considering a
drop-out rate of around 10%, total sample size required is 210
(105 per group).
Clinical Significance and Translational Outlook
of the EVA Project
The application of sex and gender medicine is strongly rec-
ommended by the World Health Organization and other inter-
national organizations [81–83]. The identification of bio-
markers and therapeutic approaches that take sex and gender
differences into proper consideration is crucial for the devel-
opment of evidence-based medicine that reflects this impor-
tant issue.
IHD is a complex and multifaceted syndrome and its path-
ophysiology includes different pieces of a single puzzle, in-
cluding factors such as atherosclerosis, inflammation, platelet
activation and vasospasm, as well as microcirculatory dys-
function worsened by abnormalities in endothelium, platelets,
mitochondria, redox signaling, ion channels, and
myocardium–blood flow cross-talk mismatch.
The EVA project will provide evidence regarding the con-
tribution of platelet function and sex hormone balance in
CMD.Moreover, the investigators expect to clarify the impact
of biological sex and gender-sensitive variables on clinical
outcomes after PCI procedure, including recurrence and re-
hospitalization.
This study will inform on biological and psychosocial de-
terminants of outcomes in IHD patients to be considered when
developing a tailored approach aimed at improving the health
of vulnerable patients. A better understanding of the interac-
tions between sex hormones and platelet pathways involved in
the development of ischemia will guide the development of
potential pharmacological strategies based on sex, aiming, in
turn, to modify the interaction between platelet and vascular
responses in the setting of coronary angiography.
Furthermore, the systematic collection of gender-related fac-
tors will contribute to the identification of the sex-specific
impact of psycho-socio-cultural factors on clinical outcomes,
providing new targets which will improve secondary preven-
tion strategies and inform policies to foster the well-being of
both women and men with IHD.
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